Trump Endorsed 'Natural 7-OH' From Kratom. Nobody Agrees on What That Means.

What Trump Said

During wide-ranging Oval Office remarks on healthcare, President Trump said his administration would seek to have "natural 7-OH" approved, gesturing toward Dr. Mehmet Oz, the CMS Administrator. His exact words, reported by Pain News Network: "We're looking very seriously at natural 7-OH and getting that approved, natural 7-OH. And we'll take a look at that very strongly. I think Oz and everybody, we're looking to see if we can do something there."

That is a reference to 7-hydroxymitragynine — 7-OH — an alkaloid derived from kratom, a plant native to Southeast Asia. The compound has pain-relieving and mood-altering properties. It is also the subject of an intensifying federal and state regulatory fight.

The Industry Split

The word "natural" is doing a lot of work in Trump's statement, and competing industry groups are pulling it in opposite directions.

Kratom leaf vendor MNG Brands interpreted the president's remarks as an endorsement of traditional whole-leaf kratom, in which 7-OH occurs naturally at concentrations typically no higher than 2%. Chief Strategy Officer Dafna Revah said in a statement, reported by Pain News Network, that MNG Brands was "encouraged by the support shown for natural leaf kratom Trump was clearly endorsing" — explicitly contrasting that with the concentrated 7-OH extracts that have proliferated in recent years.

The Holistic Alternative Recovery Trust (HART), which represents 7-OH concentrate manufacturers including American Shaman, read the same statement as a presidential greenlight for their products, including versions that contain up to 96% 7-OH. HART's argument is that their products are "natural" because 7-OH is an alkaloid that occurs in the kratom plant and is also produced by the human liver when it processes mitragynine, another kratom compound.

Both sides are claiming the same two-word phrase from the president. Neither has a written policy document, executive order, or regulatory guidance to point to.

The Case for Federal Restriction

Critics of the industry's self-regulatory framing have numbers on their side that are hard to dismiss. According to the Washington Examiner, nearly 5,300 people died from overdoses involving kratom between 2020 and 2024. The Examiner's editorial board called for an outright federal ban, labeling the drug "gas station heroin" and arguing that concentrated kratom products are being sold with less oversight than a candy bar.

A bipartisan group of senators made a more targeted but still sweeping case in March. Sen. Pete Ricketts (R-NE) and former Sen. Richard Blumenthal (D-CT) led a letter to then-FDA Commissioner Marty Makary recommending that the FDA pursue scheduling of both 7-OH and the whole kratom leaf under the Controlled Substances Act. The letter, dated March 18, 2026, was also signed by Sens. Marsha Blackburn, John Boozman, Katie Britt, Ted Budd, Mike Crapo, Steve Daines, James Justice, Alex Padilla, and Jeanne Shaheen — a Republican-heavy but genuinely bipartisan coalition.

The senators' letter warned that scheduling only 7-OH while leaving whole-leaf kratom uncontrolled would "tacitly declare" the leaf products safe and leave the market without standardized controls on concentration, labeling, or quality.

The Strongest Case for Keeping Kratom Legal

A significant number of Americans use traditional kratom, the low-concentration leaf product, for chronic pain management, opioid withdrawal support, and anxiety. For some users, especially those navigating opioid recovery without robust access to addiction medicine, kratom represents a harm-reduction option they chose deliberately over prescription opioids or illicit drugs.

The argument from groups like MNG Brands is not that kratom is without risk. Rather, they argue that conflating a whole-leaf herbal product with a 96%-concentration pharmaceutical-grade extract is bad policy. Scheduling the leaf alongside fentanyl analogues could eliminate a tool that many people use without incident while doing little to address the specific harms tied to the concentrated extracts.

That concern has face validity, and federal drug policy has a documented history of over-broad scheduling that eliminated useful compounds along with dangerous ones. The counterpoint is that kratom is currently unregulated for potency, purity, or age of sale, which is precisely the condition that allowed the concentrate market to flourish alongside the leaf market.

Where Enforcement Actually Stands

As of June 2026, kratom is federally unscheduled. Six states and Washington, D.C. have banned it outright, according to the Ricketts letter. At least 18 states have some regulatory framework. Dozens of cities and counties have specifically banned the high-concentration 7-OH products. Enforcement remains inconsistent across all of them.

No FDA scheduling action has been announced. No charges have been filed. The agency's regulatory posture under Makary, who has since resigned (a fact the Washington Examiner flagged as one of three recent headline events connected to kratom), remains unresolved under whatever leadership structure follows.

The Unresolved Question

Trump's Oval Office remark has become the primary reference point for where federal policy is heading. Yet it was two sentences, unrehearsed, with no regulatory language attached. The FDA has not issued a formal response to the Ricketts-Blumenthal letter. Until the agency either proposes a scheduling rule or explicitly declines to act, the phrase "natural 7-OH" will mean different things to different stakeholders.

The critical open question is whether the FDA, under its new leadership, will treat the president's remarks as political direction to protect the leaf market while cracking down on concentrates, or whether the bipartisan Senate pressure will push the agency toward the broader scheduling that Ricketts and Blumenthal requested in March.